These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 34731019)

  • 1. Modulating Oncolytic Adenovirus Immunotherapy by Driving Two Axes of the Immune System by Expressing 4-1BBL and CD40L.
    Lu SC; Hansen MJ; Hemsath JR; Parrett BJ; Zell BN; Barry MA
    Hum Gene Ther; 2022 Mar; 33(5-6):250-261. PubMed ID: 34731019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interference of CD40L-mediated tumor immunotherapy by oncolytic vesicular stomatitis virus.
    Galivo F; Diaz RM; Thanarajasingam U; Jevremovic D; Wongthida P; Thompson J; Kottke T; Barber GN; Melcher A; Vile RG
    Hum Gene Ther; 2010 Apr; 21(4):439-50. PubMed ID: 19922169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune response is an important aspect of the antitumor effect produced by a CD40L-encoding oncolytic adenovirus.
    Diaconu I; Cerullo V; Hirvinen ML; Escutenaire S; Ugolini M; Pesonen SK; Bramante S; Parviainen S; Kanerva A; Loskog AS; Eliopoulos AG; Pesonen S; Hemminki A
    Cancer Res; 2012 May; 72(9):2327-38. PubMed ID: 22396493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncolytic adenovirus encoding decorin and CD40 ligand inhibits tumor growth and liver metastasis via immune activation in murine colorectal tumor model.
    Rong Y; Ning Y; Zhu J; Feng P; Zhu W; Zhao X; Xiong Z; Ruan C; Jin J; Wang H; Cai T; Zhang S; Yang Y
    Mol Biomed; 2024 Sep; 5(1):39. PubMed ID: 39306655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intratumoral virotherapy with 4-1BBL armed modified vaccinia Ankara eradicates solid tumors and promotes protective immune memory.
    Hinterberger M; Giessel R; Fiore G; Graebnitz F; Bathke B; Wennier S; Chaplin P; Melero I; Suter M; Lauterbach H; Berraondo P; Hochrein H; Medina-Echeverz J
    J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33579736
    [No Abstract]   [Full Text] [Related]  

  • 6. Development of a new fusion-enhanced oncolytic immunotherapy platform based on herpes simplex virus type 1.
    Thomas S; Kuncheria L; Roulstone V; Kyula JN; Mansfield D; Bommareddy PK; Smith H; Kaufman HL; Harrington KJ; Coffin RS
    J Immunother Cancer; 2019 Aug; 7(1):214. PubMed ID: 31399043
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncolytic adenovirus-mediated intratumoral expression of TRAIL and CD40L enhances immunotherapy by modulating the tumor microenvironment in immunocompetent mouse models.
    Liu W; Wang X; Feng X; Yu J; Liu X; Jia X; Zhang H; Wu H; Wang C; Wu J; Yu B; Yu X
    Cancer Lett; 2022 Jun; 535():215661. PubMed ID: 35325845
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic and tumor-specific immunity induced by combination of dendritic cells and oncolytic adenovirus expressing IL-12 and 4-1BBL.
    Huang JH; Zhang SN; Choi KJ; Choi IK; Kim JH; Lee MG; Lee M; Kim H; Yun CO
    Mol Ther; 2010 Feb; 18(2):264-74. PubMed ID: 19738604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An adenoviral cancer vaccine co-encoding a tumor associated antigen together with secreted 4-1BBL leads to delayed tumor progression.
    Ragonnaud E; Andersson AM; Pedersen AE; Laursen H; Holst PJ
    Vaccine; 2016 Apr; 34(18):2147-56. PubMed ID: 27004934
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncolytic adenovirus decreases the proportion of TIM-3
    Liikanen I; Basnet S; Quixabeira DCA; Taipale K; Hemminki O; Oksanen M; Kankainen M; Juhila J; Kanerva A; Joensuu T; Tähtinen S; Hemminki A
    J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35193929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel Combination Oncolytic Adenoviral Gene Therapy Armed with Dm-dNK and CD40L for Breast Cancer.
    Wang Q; Yang M; Zhang Y; Zhong L; Zheng X
    Curr Gene Ther; 2019; 19(1):54-65. PubMed ID: 30848201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a potent melanoma vaccine capable of stimulating CD8(+) T-cells independently of dendritic cells in a mouse model.
    Powell KL; Stephens AS; Ralph SJ
    Cancer Immunol Immunother; 2015 Jul; 64(7):861-72. PubMed ID: 25893808
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel T cell-based vaccine capable of stimulating long-term functional CTL memory against B16 melanoma via CD40L signaling.
    Xie Y; Wang L; Freywald A; Qureshi M; Chen Y; Xiang J
    Cell Mol Immunol; 2013 Jan; 10(1):72-7. PubMed ID: 23042534
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant Adenovirus Expressing a Soluble Fusion Protein PD-1/CD137L Subverts the Suppression of CD8
    Zhang Y; Zhang H; Wei M; Mou T; Shi T; Ma Y; Cai X; Li Y; Dong J; Wei J
    Mol Ther; 2019 Nov; 27(11):1906-1918. PubMed ID: 31466933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD40 ligand and tdTomato-armed vaccinia virus for induction of antitumor immune response and tumor imaging.
    Parviainen S; Ahonen M; Diaconu I; Hirvinen M; Karttunen Å; Vähä-Koskela M; Hemminki A; Cerullo V
    Gene Ther; 2014 Feb; 21(2):195-204. PubMed ID: 24305418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Immunological killing effect of recombicant adenovirus vector rAD-mTERT-m4-1BBL on mouse hepatoma cell line Hepa1-6 cells co-cultured with T lymphocytes].
    Xiao ZS; Ma SY; Gong WD; Yao HH; DU P; Xing YQ; Wu HR
    Zhonghua Zhong Liu Za Zhi; 2009 Dec; 31(12):894-8. PubMed ID: 20193326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Host lymphodepletion enhances the therapeutic activity of an oncolytic vaccinia virus expressing 4-1BB ligand.
    Kim HS; Kim-Schulze S; Kim DW; Kaufman HL
    Cancer Res; 2009 Nov; 69(21):8516-25. PubMed ID: 19843856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative analysis of antitumor activity of CD40L, RANKL, and 4-1BBL in vivo following intratumoral administration of viral vectors or transduced dendritic cells.
    Yurkovetsky ZR; Shurin GV; Barry DA; Schuh AC; Shurin MR; Robbins PD
    J Gene Med; 2006 Feb; 8(2):129-37. PubMed ID: 16288496
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Inhibitory effect of 4-1BBL combined with Hsp70-tumor antigen peptides on pulmonary metastasis of melanoma in mice].
    Qiu H; Zhang GM; Zhang H; Yuan Y; Li D; Feng ZH
    Ai Zheng; 2005 Jul; 24(7):781-6. PubMed ID: 16004800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Boosting CAR T-cell responses in lymphoma by simultaneous targeting of CD40/4-1BB using oncolytic viral gene therapy.
    Wenthe J; Naseri S; Labani-Motlagh A; Enblad G; Wikström KI; Eriksson E; Loskog A; Lövgren T
    Cancer Immunol Immunother; 2021 Oct; 70(10):2851-2865. PubMed ID: 33666760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.